RxDoctor Payments Data

Ghazaleh Bigdeli, MD

Critical Care Medicine · Youngstown, OHNPI 1003806134

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,630 of the $10,268 with a category attached, or 74.3%. It is spread thinly across 38 manufacturers, the largest accounting for just 23.9%. Reporting peaked in 2023 at $3,714 and has fallen 66.1% since, to $1,260 in 2025. Among critical care medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,268in general payments, 2019–2025

Across 339 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Noah Medical Corporation$2K
  • AstraZeneca$2K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$453
  • United Therapeutics Corporation$446
  • Boehringer Ingelheim$391
  • plus $4K from 32 others

What the payments were for

  • Travel & lodging$2,50324%
  • Food & beverage$7,63074%
  • Education$1341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,268 in reported general payments places this provider in the 95th percentile of 285 critical care medicine providers in Ohio.

See all critical care medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$176,918
Medicare patients
520
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter312$240,994
OfevNintedanib Esylate21$172,938
NucalaMepolizumab31$124,536
Breztri AerosphereBudesonide/Glycopyr/Formoterol89$59,615
Breo ElliptaFluticasone/Vilanterol121$54,817
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr85$48,045
Stiolto RespimatTiotropium Br/Olodaterol Hcl51$26,172
Spiriva RespimatTiotropium Bromide27$18,338
Advair HfaFluticasone Propion/Salmeterol11$10,881
DuleraMometasone/Formoterol21$10,408
Combivent RespimatIpratropium/Albuterol Sulfate18$10,319
EliquisApixaban14$9,146
SymbicortBudesonide/Formoterol Fumarate26$9,039
Arformoterol Tartrate12$8,443
Albuterol Sulfate HfaAlbuterol Sulfate265$7,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,058$474,474562 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$391$227,767117 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,713$68,654115 claims
MerckDulera$255$10,40821 claims
PfizerEliquis$16$9,14614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 critical care medicine providers in Ohio.

Other critical care medicine in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →